Hydroxychloroquine is not currently used to treat patients with antiphospholipid syndrome (APS). But new research in APS-induced mice shows hydroxychloroquine may improve endothelium-dependent dilation and reduce reactive oxygen species generation…
Year in Review: The Impact of Advocacy & RheumPAC in 2018
In 2018, did you interact with the Medicare payment system, receive payment for a consultation code or worry about the Centers for Medicaid & Medicare Services (CMS) reducing reimbursement through its proposal to combine evaluation and management codes in the Physician Fee Schedule? If your answer to any of those questions is yes, then you…
2019 Changes to E/M Documentation
As of Jan. 1, 2019, the Centers for Medicare & Medicaid Services (CMS) will implement several coding and documentation policies to provide immediate burden reduction to providers. The 2019 Medicare Physician Fee Schedule Final Rule (MPFS) released Nov. 1, 2018, by the CMS contained significant changes to the Medicare Part B coding and documentation policies…
Senate Democrats Introduce Bill to Allow Government to Block Drug Price Rises
WASHINGTON (Reuters)—Four Democratic U.S. senators introduced a bill on Thursday that would allow the government to block drug price increases that it decides are unjustified. The bill sponsored by Senators Richard Blumenthal, Kamala Harris, Amy Klobuchar and Jeff Merkley, all Democrats, would allow the Department of Health and Human Services to prohibit drug price increases…
Big Data Drives New Research
Big data can benefit rheumatology research. But according to experts at the 2018 ACR/ARHP Annual Meeting, the data must first be accessible, interoperable and shareable…
ACR Delegates Move Rheumatology Concerns Forward at AMA
At the AMA’s recent House of Delegates Interim Meeting, the ACR’s delegation was able to incorporate rheumatology concerns into official AMA policy, in addition to leading a major multi-specialty resolution on the CMS-proposed move to consolidate and cut evaluation and management (E/M) services. The ACR is able to make this progress because members of the…
Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector
In a study, RA patients taking upadactinib monotherapy experienced less pain and morning joint stiffness than methotrexate-treated patients…
MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease
New research has linked the risk of developing interstitial lung disease in rheumatoid arthritis patients with the promoter variant in MUC5B, which may also contribute to the development of idiopathic pulmonary fibrosis and an unsual interstitial pneumonia seen by high-resolution CT scan…
Suleman Bhana, MD, FACR, Brings a Fresh Perspective as CMC Chair
Chairing the ACR’s Communications and Marketing Committee (CMC) can be a monumental task: The CMC is responsible for both internal and external communications to a variety of people, including rheumatology providers, patients, lawmakers, the pharmaceutical industry and others. But the CMC’s newest chair, Suleman Bhana, MD, FACR, is up for the job. The Rheumatologist recently…
Committee on Rheumatologic Care Helps Establish Principles & Position Statements
The ACR’s Committee on Rheumatologic Care (CORC) has been busy on many fronts, including establishing new position statements for the College, introducing new practice perspectives and engaging multiple stakeholders in actions to protect and enhance rheumatology practice, such as with payers. “CORC ensures the rheumatology voice is heard in all of the most critical venues,”…
- « Previous Page
- 1
- …
- 294
- 295
- 296
- 297
- 298
- …
- 814
- Next Page »